Syneron Bio Secures $150M Series B to Advance Macrocyclic Peptide Drug Discovery Platform
核心洞察
Syneron Bio (搜索) successfully closed a $150 million Series B financing round led by international life-science funds and supported by existing shareholders including AstraZeneca.
The funding will advance the company's proprietary Synova platform for intelligent macrocyclic peptide (搜索) drug discovery and accelerate clinical development of its pipeline.
The company's diversified pipeline targets oncology (搜索), autoimmune (搜索), metabolic, and rare diseases (搜索) with the goal of addressing critical unmet medical needs globally.
Syneron Bio (搜索), a leader in intelligent platform-driven macrocyclic peptide (搜索) drug discovery, announced the successful closing of its $150 million Series B financing round on Tuesday, marking a significant milestone for the biotechnology company's expansion into clinical development.
Investor Consortium and Financial Backing
The financing round was led by an international life-science fund, with co-lead participation from Decheng Capital (搜索) and CDH VGC (搜索). The investor consortium included notable participants such as a wholly owned subsidiary of the Abu Dhabi Investment Authority (搜索), True Light Capital (搜索) (an independent, wholly-owned subsidiary of Temasek (搜索)), Qiming Venture Partners (搜索), BioTrack Capital (搜索), and well-known industrial investors.
Existing shareholders demonstrated continued confidence in the company's prospects, with AstraZeneca, LAV, Sinovation Capital, 5Y Capital, GL Ventures, Biotech Development Fund, and Lenovo Capital, among others, participating in the round.
Strategic Use of Proceeds
The proceeds from this financing will be primarily allocated to two key areas: furthering the intelligent evolution of the company's proprietary macrocyclic peptide (搜索) discovery platform, Synova, and accelerating the progression of its diversified innovative pipeline into clinical development.
Frank Zhang, founder and CEO of Syneron Bio (搜索), expressed his appreciation for the investor support: "We are honored to receive support and recognition in this financing round from a distinguished group of leading global healthcare funds, tech venture capitals, reputable multi-national corporations, and prominent sovereign wealth funds."
Pipeline Development and Therapeutic Focus
The strengthened cash position will enable Syneron Bio (搜索) to accelerate the development of multiple core pipeline programs across several therapeutic areas, including oncology (搜索), autoimmune (搜索), metabolic, and rare diseases (搜索). Zhang emphasized the company's commitment to benefiting patients worldwide through these development efforts.
Platform Technology and Innovation
The company's Synova platform represents a high-throughput, intelligence-driven approach to macrocyclic peptide (搜索) drug discovery. According to Zhang, this platform will continue to scale and evolve, with the potential to significantly improve both the efficiency and success rate of macrocyclic peptide drug discovery processes.
"With the continued support of our capital and industry partners, we look forward to delivering innovative therapies and addressing critical unmet medical needs for patients around the globe," Zhang stated, outlining the company's vision for translating its platform capabilities into therapeutic solutions.